Madrigal Pharmaceuticals Inc (MDGL)
329.24
+12.15
(+3.83%)
USD |
NASDAQ |
Nov 21, 16:00
329.00
-0.24
(-0.07%)
After-Hours: 20:00
Madrigal Pharmaceuticals Net Income (Quarterly): -106.96M for Sept. 30, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -106.96M |
| June 30, 2024 | -151.97M |
| March 31, 2024 | -147.54M |
| December 31, 2023 | -112.19M |
| September 30, 2023 | -98.74M |
| June 30, 2023 | -85.80M |
| March 31, 2023 | -76.90M |
| December 31, 2022 | -85.90M |
| September 30, 2022 | -81.20M |
| June 30, 2022 | -70.73M |
| March 31, 2022 | -57.52M |
| December 31, 2021 | -64.55M |
| September 30, 2021 | -63.10M |
| June 30, 2021 | -61.65M |
| March 31, 2021 | -52.55M |
| December 31, 2020 | -59.12M |
| September 30, 2020 | -57.96M |
| June 30, 2020 | -49.02M |
| March 31, 2020 | -36.14M |
| December 31, 2019 | -27.74M |
| September 30, 2019 | -21.43M |
| June 30, 2019 | -19.70M |
| March 31, 2019 | -15.08M |
| December 31, 2018 | -11.48M |
| September 30, 2018 | -8.512M |
| Date | Value |
|---|---|
| June 30, 2018 | -6.46M |
| March 31, 2018 | -6.364M |
| December 31, 2017 | -8.445M |
| September 30, 2017 | -8.363M |
| June 30, 2017 | -8.347M |
| March 31, 2017 | -5.999M |
| December 31, 2016 | -7.749M |
| September 30, 2016 | -14.05M |
| June 30, 2016 | -2.877M |
| March 31, 2016 | -1.713M |
| December 31, 2015 | -1.883M |
| September 30, 2015 | -1.800M |
| June 30, 2015 | -19.80M |
| March 31, 2015 | -20.71M |
| December 31, 2014 | -20.35M |
| September 30, 2014 | -19.97M |
| June 30, 2014 | -22.29M |
| March 31, 2014 | -23.56M |
| December 31, 2013 | -24.16M |
| September 30, 2013 | -22.52M |
| June 30, 2013 | -22.79M |
| March 31, 2013 | -20.73M |
| December 31, 2012 | -18.12M |
| September 30, 2012 | -15.00M |
| June 30, 2012 | -14.62M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-151.97M
Minimum
Jun 2024
-27.74M
Maximum
Dec 2019
-77.36M
Average
-67.64M
Median
Net Income (Quarterly) Benchmarks
| Corcept Therapeutics Inc | 47.21M |
| ADMA Biologics Inc | 35.91M |
| 89bio Inc | -149.07M |
| Sarepta Therapeutics Inc | 33.61M |
| Matinas BioPharma Holdings Inc | -4.275M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 62.18M |
| Total Expenses (Quarterly) | 178.48M |
| EPS Diluted (Quarterly) | -4.92 |
| Enterprise Value | 6.299B |
| Gross Profit Margin (Quarterly) | 96.54% |
| Profit Margin (Quarterly) | -172.0% |
| Earnings Yield | -7.63% |
| Normalized Earnings Yield | -7.630 |